Fund Description |
The Loncar Cancer Immunotherapy ETF seeks to track the LCINDX index. It is made up of a basket of companies that develop therapies to treat cancer by harnessing the body s own immune system. Immunotherapy is a transformational field within the biotechnology space that is expected to become the foundational treatment for cancer over the next ten years. A sector ETF focusing on a unique technology like cancer immunotherapy allows investors to focus on interest areas more precisely than broad indices. LCINDX is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in this approach. |
Fund Profile |
Fund Name |
Loncar Cancer Immunotherapy ETF |
Fund Exchange Ticker |
CNCR |
Fund Sponsor |
Exchange Traded Concepts |
Fund ISIN |
US26922A8264 |
Net Expense Ratio |
0.79 % |
Fund Inception Date |
13 October 2015 |
Fund Legal Structure |
ETF (Open end fund) |
Exchange |
NASDAQ |
Listing Country Code |
US |
Fund Investment Objective |
ETF Type Specific |
US Equities - Industry Sector |
Asset Class |
Equities (Stocks) |
Index Linked |
Passive |
Index Name |
Loncar Cancer Immunotherapy Index |
Index Provider |
Loncar Investments |
Currency Hedged |
No |
Inverse / Leveraged |
Not Applicable |
Developed / Emerging |
Developed Market Funds |
Market Capitalization Range |
Broad Market / Multi-Cap |
Growth Value |
Core / Blend |
Continent |
North America |
Key Statistics |
Return As of Date |
14 January 2021 |
Asset Under Management |
52.53 Million (USD) |
1 Month Total Return |
5.86 % |
Year To Date Return |
10.34 % |
1 Year Total Return |
50.02 % |
3 Year Annualized Total Return |
11.17 % |
NAV |
35.0178 |
Share Outstanding |
1,500,000 |